Stress hyperphenylalaninemia predicts elevated mortality rates in patients with acute decompensated heart failure (ADHF). This study investigated the metabolic pathways underlying this association and ...

Synlogic has been granted a patent for genetically engineered bacteria and pharmaceutical compositions for modulating and treating diseases related to hyperphenylalaninemia. The patent also includes a ...

The latest research report Hyperphenylalaninemia (HPA) Market, covers various aspects of the industry, including market size, status, trends, and future insights for the next 10 years. It provides a ...

Hyperphenylalaninemia (HPA) is the most common amino acid metabolism defect in humans. It is an autosomal-recessive disorder of the phenylalanine (Phe) metabolism, in which high Phe concentrations and ...

PTC will use the network and life sciences capabilities of Blackstone to expand its business development works. Credit: mwooten / Pixabay. Through the funding, PTC intends to attain a constant state ...

Taiwan: A new study published in Critical Care Medicine suggests that stress-induced hyperphenylalaninemia (SHP) in patients admitted to the ICU was associated with a poor ...

Pre-treatment Phe levels over 1200 μmol/L are considered diagnostic for “classical” PKU, whereas levels between 600 and 1200 μmol/L are referred to as “atypical/mild” PKU, and 120–600 μmol/L as (mild) ...

have granted an Orphan Drug designation to its pipeline candidate PTC923 which is being developed for the treatment of patients with hyperphenylalaninemia. The company plans to begin a placebo ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to PTC923 for the treatment of patients with hyperphenylalaninemia. Hyperphenylalaninemia, a rare metabolic condition ...